Elevated retinol binding protein 4 contributes to insulin resistance in spontaneously hypertensive rats

Hormone and Metabolic Research

Volumn 43, Issue 5, 2011, Pages 312-318

  Ou, H Y ^a   Wu, H T ^a   Yang, Y C ^a   Wu, J S ^a   Cheng, J T ^b,c   Chang, C J ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

diabetes; insulin resistance; retinol binding protein 4; spontaneously hypertensive rats; valsartan

Indexed keywords

ADIPONECTIN; FENRETINIDE; GLUCOSE TRANSPORTER 4; INSULIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RETINOL BINDING PROTEIN 4; VALSARTAN;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE EXACERBATION; GLUCOSE METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; URINARY EXCRETION; WESTERN BLOTTING; WHITE ADIPOSE TISSUE; WISTAR KYOTO RAT;

ANGIOTENSIN AMIDE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INSULIN RESISTANCE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RETINOL-BINDING PROTEINS, PLASMA;

ANIMALIA; RATTUS;

EID: 79955690236     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1271746     Document Type: Article

References (46)

1. Gu Q, Dillon CF, Burt VL, Gillum RF. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens 2009; 23: 38-45
2. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812-819 (Pubitemid 44415613)
3. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992; 231: 235-240
4. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-174 (Pubitemid 20053276)
5. Skarfors ET, Lithell HO, Selinus I. Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 1991; 9: 217-223
6. Blaner WS. Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev 1989; 10: 308-316 (Pubitemid 19223063)
7. van Dam RM, Hu FB. Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2? Clin Chem 2007; 53: 5-7
8. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457-2461 (Pubitemid 44912252)
9. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson P-A, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563 (Pubitemid 43882351)
10. Jia W, Wu H, Bao Y, Wang C, Lu J, Zhu J, Xiang K. Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 3224-3229 (Pubitemid 47236396)
11. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007; 92: 2712-2719 (Pubitemid 47037380)
12. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche A, Haring HU. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 2007; 30: 1173-1178 (Pubitemid 46684644)
13. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362 (Pubitemid 41065039)
14. Ost A, Danielsson A, Liden M, Eriksson U, Nystrom FH, Stralfors P. Retinol- binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. FASEB J 2007; 21: 3696-3704 (Pubitemid 350075157)
15. Raila J, Henze A, Spranger J, Mohlig M, Pfeiffer AF, Schweigert FJ. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int 2007; 72: 505-511 (Pubitemid 47237617)
16. Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism 2007; 56: 327-331
17. Solini A, Santini E, Madec S, Rossi C, Muscelli E. Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens 2009; 22: 1001-1006
18. Reaven GM, Chang H. Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in spontaneous hypertensive and Wistar-Kyoto rats. Am J Hypertens 1991; 4: 34-38
19. Swislocki AL, Goodman MN, Khuu DT, Fann KY. Insulin resistance and hypertension: in vivo and in vitro insulin action in skeletal muscle in spontaneously hypertensive and Wistar-Kyoto rats. Am J Hypertens 1997; 10: 1159-1164 (Pubitemid 27488579)
20. Reaven GM, Chang H, Hoffman BB, Azhar S. Resistance to insulin-stimulated glucose uptake in adipocytes isolated from spontaneously hypertensive rats. Diabetes 1989; 38: 1155-1160 (Pubitemid 19250402)
21. Mondon CE, Reaven GM. Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metabolism 1988; 37: 303-305
22. Reaven GM, Chang H. Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in spontaneous hypertensive and Wistar-Kyoto rats. Am J Hypertens 1991; 4: 34-38
23. Labat C, Lacolley P, Lajemi M, de Gasparo M, Safar ME, Benetos A. Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Hypertension 2001; 38: 439-443 (Pubitemid 34225680)
24. Schaffer EM, Ritter SJ, Smith JE. N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats. J Nutr 1993; 123: 1497-1503 (Pubitemid 23268001)
25. Zemancikova A, Torok J. Effect of chronic nifedipine treatment on blood pressure and adrenergic responses of isolated mesenteric artery in young rats with developing spontaneous hypertension. Physiol Res 2009; 58: 921-925
26. Berni R, Formelli F. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett 1992; 308: 43-45
27. Swislocki A, Tsuzuki A. Insulin resistance and hypertension: glucose intolerance, hyperinsulinemia, and elevated free fatty acids in the lean spontaneously hypertensive rat. Am J Med Sci 1993; 306: 282-286 (Pubitemid 23327637)
28. Rao RH. Insulin resistance in spontaneously hypertensive rats. Difference in interpretation based on insulin infusion rate or on plasma insulin in glucose clamp studies. Diabetes 1993; 42: 1364-1371
29. Bader S, Scholz R, Kellerer M, Tippmer S, Rett K, Mathaei S, Freund P, Haring HU. Normal insulin receptor tyrosine kinase activity and glucose transporter (GLUT 4) levels in the skeletal muscle of hyperinsulinaemic hypertensive rats. Diabetologia 1992; 35: 712-718
30. Kahn CR, Saad MJ. Alterations in insulin receptor and substrate phosphorylation in hypertensive rats. J Am Soc Nephrol 1992; 3: S69-S77
31. Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 2006; 13: 51-68
32. Camerini T, Mariani L, De Palo G, Marubini E, Di Mauro MG, Decensi A, Costa A, Veronesi U. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001; 19: 1664-1670 (Pubitemid 32230866)
33. Harris G, Ghazallah RA, Nascene D, Wuertz B, Ondrey FG. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR. Otolaryngol Head Neck Surg 2005; 133: 695-701 (Pubitemid 41586056)
34. Potenza MA, Marasciulo FL, Tarquinio M, Quon MJ, Montagnani M. Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. Diabetes 2006; 55: 3594-3603 (Pubitemid 44923622)
35. Preitner F, Mody N, Graham TE, Peroni OD, Kahn BB. Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis. Am J Physiol Endocrinol Metab 2009; 297: E1420-E1429
36. Chan P, Wong KL, Liu IM, Tzeng TF, Yang TL, Cheng JT. Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin- induced diabetic rats. J Hypertens 2003; 21: 761-769 (Pubitemid 36549672)
37. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E, Boger RH. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55: 1159-1164 (Pubitemid 44219053)
38. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008; 21: 206-212 (Pubitemid 351231578)
39. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006; 45: 154-162 (Pubitemid 44716729)
40. Lee JM, Kim JH, Son HS, Hong EG, Yu JM, Han KA, Min KW, Chang SA. Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. J Int Med Res 2010; 38: 234-241
41. Makita S, Abiko A, Naganuma Y, Moriai Y, Nakamura M. Potential effects of angiotensin II receptor blockers on glucose tolerance and adiponectin levels in hypertensive patients. Cardiovasc Drugs Ther 2007; 21: 317-318 (Pubitemid 47387471)
42. Ozaki N, Nomura Y, Sobajima H, Kondo K, Oiso Y. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. Eur J Intern Med 2010; 21: 236-239
43. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010; 55: 715-721
44. Younis F, Stern N, Limor R, Oron Y, Zangen S, Rosenthal T. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation. Metabolism 2010; 59: 1200-1209
45. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-2261 (Pubitemid 39625096)
46. Pscherer S, Heemann U, Frank H. Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance. Diabetes Care 2010; 33: 914-919